Clinical Trials Browser

Neoplasm, Residual × blinatumomab × 30 days × Clear all

NCT04521231 2026-03-06

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07443592 2026-03-02

LAL-2025

Phase NA Not yet recruiting

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma